Ever Supreme Bio Technology Co. Ltd
6712.TWO
| Exchange: | TWO |
| Currency | New Taiwan Dollar |
| Fiscal Year End: | December |
| Sector: | Healthcare |
| Industry: | Biotechnology |
| Description: | Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells. Its products include UMC01, a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke; ADCV01, a drug candidate in Phase II clinical trials for the treatment of malignant brain tumor; CAR001, a chimeric antigen receptor immune cells product; and bone-marrow stem cells (BMSC), used to treat chronic stroke, degenerative osteoarthritis, and spinal cord injuries. The company was incorporated in 2016 and is based in Taichung, Taiwan. |
| Address: | No. 30, Keya Road, Taichung, Taiwan |
| Website: | https://www.ever-supreme.com.tw |
| Updated On: | 2024-11-09 |
Highlights
| Market Capitalization: | 14561403904 |
| Market Capitalization Mln: | 14561.40 |
| EBITDA: | 420734016 |
| PE Ratio: | 28.88 |
| Book Value: | 19.09 |
| Dividend Share: | 5.45 |
| Dividend Yield: | 0.03 |
| Earnings Share: | 6.25 |
| Most Recent Quarter: | 2024-06-30 |
| Profit Margin: | 0.62 |
| Operating Margin TTM: | 0.43 |
| Return On Assets TTM: | 0.13 |
| Return On Equity TTM: | 0.30 |
| Revenue TTM: | 823569984 |
| Revenue Per Share TTM: | 10.15 |
| Quarterly Revenue Growth YOY: | 0.11 |
| Diluted Eps TTM: | 6.25 |
| Quarterly Earnings Growth YOY: | 1.34 |
Valuation
| Trailing PE: | 28.88 |
| Price Sales TTM: | 17.68 |
| Price Book MRQ: | 9.45 |
| Enterprise Value: | 13920162841 |
| Enterprise Value Revenue: | 16.90 |
| Enterprise Value Ebitda: | 21.97 |
Shares
| Shares Outstanding: | 80672600 |
| Shares Float: | 57880457 |
| Percent Insiders: | 31.76 |
| Percent Institutions: | 2.60 |
Technicals
| Beta: | 0.30 |
| 52 Week High: | 215 |
| 52 Week Low: | 164.00 |
| 50 Day MA: | 181.96 |
| 200 Day MA: | 187.69 |
Splits & Dividends
| Forward Annual Dividend Rate: | 6 |
| Forward Annual Dividend Yield: | 0.03 |
| Payout Ratio: | 0.04 |
| Ex Dividend Date: | 2024-05-29 |
| Last Split Factor: | 1100:1000 |
| Last Split Date: | 2024-05-29 |
Earnings
| Report Date: | 2024-03-15 |
| Date: | 2023-12-31 |
| Before After Market: | After Market |
| Eps Actual: | 1.34 |
| Eps Estimate: | 1.33 |
| Eps Difference: | 0.01 |
| Surprise Percent: | 0.75 |
| Report Date: | 2023-10-16 |
| Date: | 2023-09-30 |
| Before After Market: | After Market |
| Eps Actual: | 3.68 |
| Eps Estimate: | 1.09 |
| Eps Difference: | 2.59 |
| Surprise Percent: | 237.61 |
| Date: | 2025-12-31 |
| Period: | +1y |
| Date: | 2024-12-31 |
| Revenue Estimate Avg: | 785000000.00 |
| Revenue Estimate Low: | 785000000.00 |
| Revenue Estimate High: | 785000000.00 |
| Revenue Estimate Number Of Analysts: | 1.00 |
| Revenue Estimate Growth: | 0.03 |
| Eps Trend7days Ago: | 4.85 |
| Eps Trend30days Ago: | 4.85 |
| Eps Trend60days Ago: | 4.85 |
| Eps Trend90days Ago: | 4.85 |
| Date: | 2024-06-30 |
| Period: | +1q |
| Revenue Estimate Low: | 170000000.00 |
| Revenue Estimate High: | 170000000.00 |
| Revenue Estimate Number Of Analysts: | 1.00 |
| Eps Trend7days Ago: | 1.52 |
| Eps Trend30days Ago: | 1.52 |
| Eps Trend60days Ago: | 1.52 |
| Eps Trend90days Ago: | 1.52 |
| Date: | 2024-03-31 |
| Revenue Estimate Low: | 141000000.00 |
| Revenue Estimate High: | 141000000.00 |
| Revenue Estimate Number Of Analysts: | 1.00 |
| Eps Trend7days Ago: | 0.72 |
| Eps Trend30days Ago: | 0.72 |
| Eps Trend60days Ago: | 0.72 |
| Eps Trend90days Ago: | 0.72 |
| Date: | 2023-12-31 |
| Eps Actual: | 5.0 |